About Us

Welcome to Maculaser, where innovation meets compassion in the realm of retinal care. Our groundbreaking retinal treatment leverages personalized heating to awaken the natural healing response of senescent cells. With a dedicated focus on disease prevention, we provide a non-damaging solution to address retinal disorders that impact millions globally.

Our Vision

Rooted in pioneering research in the top biomedical engineering laboratory at Aalto University, Finland, since 2013, Maculaser aims to revolutionize retinal healthcare. Targeting conditions like Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Central Serous Chorioretinopathy (CSC), we strive to tackle the root causes of the diseases and make prevention a cornerstone of eye care. Our journey is advancing towards initiating our clinical trials.

Company Values

Focusing on patient safety, committed to science and evidence-based approaches, driven by outcome orientation, and inspired by engineering curiosity, our company values guide us to innovate and improve healthcare solutions. Each principle is integral to our dedication to advancing medical technology with integrity, precision, and a forward-thinking mindset.

Our Team

Jani Tirronen

CEO

Teemu Turunen

Chief Scientific Officer, PhD

Ossi Kaikkonen

Head of Product

Jaakko Nieminen

CTO, PhD

Kirsty Happonen

Head of RAQA

Risto Montonen

Senior R&D Engineer, PhD

Aki Vartiainen

Clinical Trial Manager

Contact us

    Follow how our solution develops


    • New Clinical Trial Manager joins Maculaser

      We are pleased to announce that Aki Vartiainen joins the Maculaser team as Clinical Trial Manager.Aki brings strong expertise to our […]

      Read more ›


    • Maculaser secures its first Japanese patent

      Maculaser has been granted a Japanese patent for its method and device for determining changes in retinal and/or brain temperature. […]

      Read more ›


    • Maculaser’s retinal treatment technology exhibited in Media

      Finnish new technology focused magazine T&T (Tekniikka ja Talous) reports on Maculaser’s goals and timeline in developing novel treatments for […]

      Read more ›

    Scroll to Top